Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Revenue (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Revenue for 17 consecutive years, with $209.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue changed 0.38% to $209.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $824.5 million, a 1.56% decrease, with the full-year FY2025 number at $824.5 million, down 1.56% from a year prior.
  • Revenue was $209.8 million for Q4 2025 at Myriad Genetics, up from $205.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $213.3 million in Q3 2024 to a low of $156.4 million in Q3 2022.
  • A 5-year average of $189.2 million and a median of $190.6 million in 2021 define the central range for Revenue.
  • Biggest YoY gain for Revenue was 103.22% in 2021; the steepest drop was 46.36% in 2021.
  • Myriad Genetics' Revenue stood at $160.8 million in 2021, then grew by 10.57% to $177.8 million in 2022, then rose by 10.57% to $196.6 million in 2023, then increased by 7.12% to $210.6 million in 2024, then dropped by 0.38% to $209.8 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Revenue are $209.8 million (Q4 2025), $205.7 million (Q3 2025), and $213.1 million (Q2 2025).